Pamela Ann Connealy - Net Worth and Insider Trading

Pamela Ann Connealy Net Worth

The estimated net worth of Pamela Ann Connealy is at least $4 Million dollars as of 2024-05-04. Pamela Ann Connealy is the CFO and COO of Pyxis Oncology Inc and owns about 818,532 shares of Pyxis Oncology Inc (PYXS) stock worth over $4 Million. Details can be seen in Pamela Ann Connealy's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Pamela Ann Connealy has not made any transactions after 2023-09-28 and currently still holds the listed stock(s).

Transaction Summary of Pamela Ann Connealy

To

Pamela Ann Connealy Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Pamela Ann Connealy owns 5 companies in total, including Immunovant Inc (IMVTU) , Immunovant Inc (IMVT) , and Pyxis Oncology Inc (PYXS) among others .

Click here to see the complete history of Pamela Ann Connealy’s form 4 insider trades.

Insider Ownership Summary of Pamela Ann Connealy

Ticker Comapny Transaction Date Type of Owner
IMVTU Immunovant Inc 2020-05-15 Chief Financial Officer
IMVT Immunovant Inc 2019-12-18 Chief Financial Officer
PYXS Pyxis Oncology Inc 2023-09-28 Chief Financial Officer
2023-01-26 director
2023-07-20 director

Pamela Ann Connealy Latest Holdings Summary

Pamela Ann Connealy currently owns a total of 1 stock. Pamela Ann Connealy owns 818,532 shares of Pyxis Oncology Inc (PYXS) as of September 28, 2023, with a value of $4 Million.

Latest Holdings of Pamela Ann Connealy

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PYXS Pyxis Oncology Inc 2023-09-28 818,532 4.38 3,585,170

Holding Weightings of Pamela Ann Connealy


Pamela Ann Connealy Form 4 Trading Tracker

According to the SEC Form 4 filings, Pamela Ann Connealy has made a total of 4 transactions in Pyxis Oncology Inc (PYXS) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Pyxis Oncology Inc is the acquisition of 8,000 shares on September 28, 2023, which cost Pamela Ann Connealy around $14,960.

Insider Trading History of Pamela Ann Connealy

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Pamela Ann Connealy Trading Performance

GuruFocus tracks the stock performance after each of Pamela Ann Connealy's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pamela Ann Connealy is -4.43%. GuruFocus also compares Pamela Ann Connealy's trading performance to market benchmark return within the same time period. The performance of stocks bought by Pamela Ann Connealy within 3 months outperforms 0 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Pamela Ann Connealy's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Pamela Ann Connealy

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -11.75
Relative Return to S&P 500(%) -8.35

Pamela Ann Connealy Ownership Network

Ownership Network List of Pamela Ann Connealy

No Data

Ownership Network Relation of Pamela Ann Connealy


Pamela Ann Connealy Owned Company Details

What does Immunovant Inc do?

Who are the key executives at Immunovant Inc?

Pamela Ann Connealy is the Chief Financial Officer of Immunovant Inc. Other key executives at Immunovant Inc include 10 percent owner Roivant Sciences Ltd. , Chief Dev. & Tech. Officer Julia G. Butchko , and Chief Scientific Officer Michael James Elliott .

Immunovant Inc (IMVTU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immunovant Inc (IMVTU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunovant Inc (IMVTU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunovant Inc (IMVTU)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Immunovant Inc Insider Transactions

No Available Data

Pamela Ann Connealy Mailing Address

Above is the net worth, insider trading, and ownership report for Pamela Ann Connealy. You might contact Pamela Ann Connealy via mailing address: 320 W 37th Street, 3rd Floor, New York Ny 10016.

Discussions on Pamela Ann Connealy

No discussions yet.